General
Preferred name
PIBRENTASVIR
Synonyms
ABT 530 ()
ABT-530 ()
ABT530 ()
Mavyret-pibrentasvir ()
Pibrentasvir (ABT-530) ()
A-1325912.0 ()
P&D ID
PD060942
CAS
1353900-92-1
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2017
Drug Status
investigational
approved
Drug indication
Hepatitis C virus infection
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh; A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor; or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DESCRIPTION Pibrentasvir is an oral, direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex. It targets viral RNA replication and viron assembly. (GtoPdb)
DESCRIPTION Pibrentasvir is an antiviral agent that inhibits HCV non-structural protein 5A (NS5A). It inhibits HCV RNA replication and viron assembly. In combination with glecaprevir, a HCV NS3/4A protease inhibitor, pibrentasvir is used to treat patients with HCV infections who experienced therapeutic failure from other NS5A inhibitors. (BOC Sciences Bioactive Compounds)
Compound Sets
16
BOC Sciences Bioactive Compounds
pibrentasvir-cas-1353900-92-1-291729
Cayman Chemical Bioactives
27546
ChEMBL Approved Drugs
CHEMBL3545123
ChEMBL Drugs
CHEMBL3545123
DrugBank
DB13878
DrugBank Approved Drugs
DB13878
DrugCentral
5244
DrugCentral Approved Drugs
5244
DrugMAP
DM27BL1
DrugMAP Approved Drugs
DM27BL1
Guide to Pharmacology
11268
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
2WU922TK3L
ReFrame library
Selleckchem Bioactive Compound Library
pibrentasvir-abt-530-
TargetMol Bioactive Compound Library
T5127
External IDs
23
Properties
(calculated by RDKit )
Molecular Weight
1112.49
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
4
Rotatable Bonds
15
Ring Count
10
Aromatic Ring Count
6
cLogP
9.86
TPSA
206.56
Fraction CSP3
0.47
Chiral centers
8.0
Largest ring
6.0
QED
0.04
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Target
HCV NS5A
MOA
HCV Protease
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antiviral
Therapeutic Class
Antiviral Agent
Source data